Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.10
ALR's Cash to Debt is ranked lower than
55% of the 297 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.89 vs. ALR: 0.10 )
ALR' s 10-Year Cash to Debt Range
Min: 0.09   Max: 1.88
Current: 0.1

0.09
1.88
Equity to Asset 0.29
ALR's Equity to Asset is ranked higher than
51% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.62 vs. ALR: 0.29 )
ALR' s 10-Year Equity to Asset Range
Min: -0.26   Max: 0.66
Current: 0.29

-0.26
0.66
Interest Coverage 0.45
ALR's Interest Coverage is ranked lower than
57% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 257.77 vs. ALR: 0.45 )
ALR' s 10-Year Interest Coverage Range
Min: 0.04   Max: 3.6
Current: 0.45

0.04
3.6
F-Score: 6
Z-Score: 0.81
M-Score: -2.65
WACC vs ROIC
10.33%
3.74%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 3.30
ALR's Operating margin (%) is ranked higher than
76% of the 290 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.79 vs. ALR: 3.30 )
ALR' s 10-Year Operating margin (%) Range
Min: -92.15   Max: 13.42
Current: 3.3

-92.15
13.42
Net-margin (%) 0.38
ALR's Net-margin (%) is ranked higher than
73% of the 290 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.93 vs. ALR: 0.38 )
ALR' s 10-Year Net-margin (%) Range
Min: -149.74   Max: 6.61
Current: 0.38

-149.74
6.61
ROE (%) 0.49
ALR's ROE (%) is ranked higher than
73% of the 273 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.49 vs. ALR: 0.49 )
ALR' s 10-Year ROE (%) Range
Min: -555.34   Max: 10.39
Current: 0.49

-555.34
10.39
ROA (%) 0.14
ALR's ROA (%) is ranked higher than
74% of the 299 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.00 vs. ALR: 0.14 )
ALR' s 10-Year ROA (%) Range
Min: -104.38   Max: 3.56
Current: 0.14

-104.38
3.56
ROC (Joel Greenblatt) (%) 7.51
ALR's ROC (Joel Greenblatt) (%) is ranked higher than
75% of the 297 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.09 vs. ALR: 7.51 )
ALR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -445.57   Max: 66.78
Current: 7.51

-445.57
66.78
Revenue Growth (3Y)(%) 2.80
ALR's Revenue Growth (3Y)(%) is ranked higher than
68% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.20 vs. ALR: 2.80 )
ALR' s 10-Year Revenue Growth (3Y)(%) Range
Min: -8.6   Max: 73
Current: 2.8

-8.6
73
EBITDA Growth (3Y)(%) -0.20
ALR's EBITDA Growth (3Y)(%) is ranked higher than
71% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.90 vs. ALR: -0.20 )
ALR' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -39.4   Max: 103.3
Current: -0.2

-39.4
103.3
EPS Growth (3Y)(%) 13.00
ALR's EPS Growth (3Y)(%) is ranked higher than
87% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.20 vs. ALR: 13.00 )
ALR' s 10-Year EPS Growth (3Y)(%) Range
Min: -57.9   Max: 75.3
Current: 13

-57.9
75.3
» ALR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

ALR Guru Trades in Q2 2014

John Keeley 1,335,700 sh (New)
Joel Greenblatt 11,057 sh (New)
Paul Tudor Jones 5,800 sh (New)
Mario Gabelli 242,845 sh (+206.84%)
Pioneer Investments 469,046 sh (+72.39%)
Chuck Royce 686,700 sh (+11.53%)
Diamond Hill Capital 1,066,212 sh (+8.05%)
Private Capital 920,989 sh (-1.55%)
Manning & Napier Advisors, Inc 4,431,073 sh (-7.87%)
Jim Simons 74,924 sh (-74.54%)
» More
Q3 2014

ALR Guru Trades in Q3 2014

Steven Cohen 1,994,100 sh (New)
Jim Simons 162,900 sh (+117.42%)
Diamond Hill Capital 2,239,478 sh (+110.04%)
Mario Gabelli 263,770 sh (+8.62%)
John Keeley 1,342,615 sh (+0.52%)
Pioneer Investments 541,795 sh (unchged)
Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
Private Capital 908,453 sh (-1.36%)
Manning & Napier Advisors, Inc 3,300,883 sh (-25.51%)
Chuck Royce 268,200 sh (-60.94%)
» More
Q4 2014

ALR Guru Trades in Q4 2014

Joel Greenblatt 382,075 sh (New)
Jim Simons 390,124 sh (+139.49%)
Diamond Hill Capital 2,669,006 sh (+19.18%)
John Keeley 1,349,075 sh (+0.48%)
Private Capital 902,223 sh (-0.69%)
Chuck Royce 222,700 sh (-16.96%)
Mario Gabelli 203,100 sh (-23.00%)
Steven Cohen 1,529,167 sh (-23.32%)
Manning & Napier Advisors, Inc 1,313,248 sh (-60.22%)
Manning & Napier Advisors, Inc 1,313,248 sh (-60.22%)
Pioneer Investments 166,304 sh (-69.30%)
» More
Q1 2015

ALR Guru Trades in Q1 2015

Manning & Napier Advisors, Inc 838,826 sh (-36.13%)
» More
» Details

Insider Trades

Latest Guru Trades with ALR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Alere Inc

SymbolPriceYieldDescription
ALRPRB15.423.56

Guru Investment Theses on Alere Inc

Diamond Hill Capital Comments on Alere Inc - Mar 17, 2015

Diagnostic systems provider Alere, Inc. (ALR) declined after installing a new CEO during the quarter, while weathering an unsolicited attempt by the previous CEO to take the company private. Subsequently, the company announced that it would sell its Health Management business in a first sign of the implementation of a new agenda focused on asset sales and debt paydown.

From Diamond Hill Capital (Trades, Portfolio)’s Select Fund Q4 2014 Commentary.

Check out Diamond Hill Capital latest stock trades

Mario Gabelli Comments on Alere Inc - Nov 21, 2014

Alere Inc. (0.2% of net assets as of September 30, 2014) (ALR - $38.78 - NYSE) is the largest manufacturer of rapid, point-of-care diagnostics in the world. The company has underperformed for the past year, weighed down by manufacturing problems and a heavy debt load from questionable past acquisitions. An activist investor has been publicly pushing the company to improve operations and, after being slow to respond initially, Alere’s Board of Directors forced the company’s founder and CEO to resign on July 1. However, he has now partnered with private equity partners and is seeking to take the company private with an initial bid of $46 per share. Whatever the final outcome is, we believe positive change is in the air for Alere.

From Mario Gabelli (Trades, Portfolio)’s Asset Fund Q3 2014 Commentary.

Check out Mario Gabelli latest stock trades

Diamond Hill Capital Comments on Alere Inc - Oct 17, 2014

We initiated a new position in diagnostic systems provider Alere, Inc (ALR). We believe the company has the potential to grow intrinsic value by focusing on cost savings, asset disposals, and debt pay-down. All three of these initiatives would represent avenues to unmask the true long-term earnings power of the company and its core point-of-care diagnostics business. We forecast earnings well above the current consensus estimates.

From Diamond Hill Capital (Trades, Portfolio)'s Select Fund Third Quarter 2014 Commentary.

Check out Diamond Hill Capital latest stock trades

Top Ranked Articles about Alere Inc

Diamond Hill Capital Comments on Alere Inc
Diagnostic systems provider Alere, Inc. (ALR) declined after installing a new CEO during the quarter, while weathering an unsolicited attempt by the previous CEO to take the company private. Subsequently, the company announced that it would sell its Health Management business in a first sign of the implementation of a new agenda focused on asset sales and debt paydown. Read more...
Mario Gabelli Comments on Alere Inc
Alere Inc. (0.2% of net assets as of September 30, 2014) (ALR - $38.78 - NYSE) is the largest manufacturer of rapid, point-of-care diagnostics in the world. The company has underperformed for the past year, weighed down by manufacturing problems and a heavy debt load from questionable past acquisitions. An activist investor has been publicly pushing the company to improve operations and, after being slow to respond initially, Alere’s Board of Directors forced the company’s founder and CEO to resign on July 1. However, he has now partnered with private equity partners and is seeking to take the company private with an initial bid of $46 per share. Whatever the final outcome is, we believe positive change is in the air for Alere. Read more...
Diamond Hill Capital Comments on Alere Inc
We initiated a new position in diagnostic systems provider Alere, Inc (ALR). We believe the company has the potential to grow intrinsic value by focusing on cost savings, asset disposals, and debt pay-down. All three of these initiatives would represent avenues to unmask the true long-term earnings power of the company and its core point-of-care diagnostics business. We forecast earnings well above the current consensus estimates. Read more...

Ratios

vs
industry
vs
history
Forward P/E 18.38
ALR's Forward P/E is ranked higher than
88% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. ALR: 18.38 )
N/A
P/B 3.10
ALR's P/B is ranked higher than
71% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.90 vs. ALR: 3.10 )
ALR' s 10-Year P/B Range
Min: 0.42   Max: 3.1
Current: 3.1

0.42
3.1
P/S 1.60
ALR's P/S is ranked higher than
86% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.52 vs. ALR: 1.60 )
ALR' s 10-Year P/S Range
Min: 0.52   Max: 4.12
Current: 1.6

0.52
4.12
PFCF 31.60
ALR's PFCF is ranked higher than
82% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. ALR: 31.60 )
ALR' s 10-Year PFCF Range
Min: 7.62   Max: 135.97
Current: 31.6

7.62
135.97
POCF 17.58
ALR's POCF is ranked higher than
90% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. ALR: 17.58 )
ALR' s 10-Year POCF Range
Min: 4.63   Max: 132.61
Current: 17.58

4.63
132.61
EV-to-EBIT 95.26
ALR's EV-to-EBIT is ranked higher than
76% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. ALR: 95.26 )
ALR' s 10-Year EV-to-EBIT Range
Min: -884.5   Max: 2833.4
Current: 95.26

-884.5
2833.4
Current Ratio 2.46
ALR's Current Ratio is ranked higher than
70% of the 290 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.52 vs. ALR: 2.46 )
ALR' s 10-Year Current Ratio Range
Min: 0.73   Max: 3.42
Current: 2.46

0.73
3.42
Quick Ratio 1.97
ALR's Quick Ratio is ranked higher than
68% of the 290 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.17 vs. ALR: 1.97 )
ALR' s 10-Year Quick Ratio Range
Min: 0.56   Max: 2.89
Current: 1.97

0.56
2.89
Days Inventory 97.62
ALR's Days Inventory is ranked higher than
75% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 139.33 vs. ALR: 97.62 )
ALR' s 10-Year Days Inventory Range
Min: 38.42   Max: 130.6
Current: 97.62

38.42
130.6
Days Sales Outstanding 65.75
ALR's Days Sales Outstanding is ranked higher than
79% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 78.80 vs. ALR: 65.75 )
ALR' s 10-Year Days Sales Outstanding Range
Min: 51.97   Max: 166.61
Current: 65.75

51.97
166.61

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.40
ALR's Price/DCF (Projected) is ranked higher than
93% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. ALR: 1.40 )
ALR' s 10-Year Price/DCF (Projected) Range
Min: 0.44   Max: 5.18
Current: 1.4

0.44
5.18
Price/Median PS Value 1.20
ALR's Price/Median PS Value is ranked higher than
76% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. ALR: 1.20 )
ALR' s 10-Year Price/Median PS Value Range
Min: 0.39   Max: 3.05
Current: 1.2

0.39
3.05
Earnings Yield (Greenblatt) 1.00
ALR's Earnings Yield (Greenblatt) is ranked higher than
69% of the 295 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.50 vs. ALR: 1.00 )
ALR' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.3   Max: 2.9
Current: 1

0.3
2.9

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, DGX, LIFE, ENZ, IDXX » details
Traded in other countries:IM5.Germany,
Alere Inc formerly known as Inverness Medical Innovations, Inc. is a Delaware corporation incorporated on August 25,1992, which was formed to acquire the women's health, nutritional supplements and professional diagnostics businesses of its predecessor, Inverness Medical Technology, Inc., through a split-off and merger transaction, which occurred in November 2001. The Company enables individuals to take control of their health at home, under the supervision of their healthcare providers, by connecting innovative diagnostics in the hands of patients to their healthcare providers. The Company is a provider of point-of-care diagnostics and services; and has developed a strong commercial presence in infectious disease, toxicology, cardiology and diabetes. Its products and services help healthcare practitioners make earlier, more effective treatment decisions and improve outcomes for individuals living with chronic disease. Its portfolio also includes a broad array of health information solutions that increase access to critical health data, provide clinical decision support and facilitate more comprehensive performance reporting and analysis. The Company's operating segments are professional diagnostics, health information solutions and consumer diagnostics. Professional Diagnostics solutions allow patients and their healthcare providers to work together to better manage patients' chronic conditions over the continuum of care, from the hospital to home. It is generally designed to assist medical professionals in both preventative and interventional medicine, and include testing and monitoring performed in hospitals, laboratories and doctors' offices and, increasingly, patient self-testing, which defined as testing or monitoring performed at home under the supervision of a medical professional. Its products provide for qualitative or quantitative analysis of patient samples for evidence of a specific medical condition, disease state or toxicological state or to measure response to therapy. In professional diagnostics, Company focus on point-of-care, rapid diagnostic testing and the developing patient self-testing and patient self-management markets where it can directly and immediately improve patient health outcomes. Its products include point-of-care and laboratory tests within the following areas; Infectious Disease, Toxicology, Cardiology, Diabetes, Oncology, Women's Health and Connected Device Technologies. Its health information solutions are designed to provide physicians with actionable data that allows them to make more effective decisions in real time, deliver quality care, and put the individuals they treat on a pathway to better health. It offers a variety of software-based analytics, clinical decision-support tools, and accountable care programs that enable healthcare providers to initiate earlier interventions, personalize treatment plans, lower costs by reducing hospital readmissions, and measure improvements in outcome
» More Articles for ALR

Headlines

Articles On GuruFocus.com
Diamond Hill Capital Comments on Alere Inc Mar 17 2015 
Corsair Capital's Analysis of Alere Mar 06 2015 
DENTSPLY´s Growth Opportunities Dec 16 2014 
Hologic Produces the First FDA-Approved 3D Mammography Platform Nov 26 2014 
Mario Gabelli Comments on Alere Inc Nov 21 2014 
Mario Gabelli’s Asset Fund Q3 2014 Commentary Nov 21 2014 
Cohen Has Busy Third Quarter Nov 19 2014 
Alder Reports Encouraging Copper and Gold Metallurgical Recovery Results for the Stockpiles and Tail Nov 05 2014 
Diamond Hill Capital Comments on Alere Inc Oct 17 2014 
Diamond Hill Select Fund Third Quarter 2014 Commentary Oct 17 2014 


More From Other Websites
James Pallotta’s Raptor Capital Hits Homerun with Hospira, Inc. (HSP) Apr 17 2015
Altera Announces First Quarter Earnings Conference Call Apr 16 2015
Closing of the placement of the series H shares – supplement to current report no. 17/2015 of 4... Apr 16 2015
Notification of transactions on the Bank’s shares Apr 13 2015
Altera Joins Industrial Internet Consortium to Influence Global Ecosystem for Internet of Things Apr 13 2015
Altera to Demonstrate Ultra HD End-to-End Solutions at NAB 2015 Apr 09 2015
Altera and TSMC Innovate Industry-first, UBM-free WLCSP Packaging Technology Platform for MAX® 10... Apr 07 2015
Alere Inc. Reports Employment Inducement Awards Pursuant to NYSE Rule 303A.08 Apr 06 2015
Alere Inc. Reports Employment Inducement Awards Pursuant to NYSE Rule 303A.08 Apr 06 2015
Alere Wins FDA Nod for Strep A Test, Applies for CLIA Waiver - Analyst Blog Apr 06 2015
Information about a change in the share in the total number of votes Apr 02 2015
Alere Receives FDA Clearance for Alere™ i Strep A Rapid Molecular Test Apr 02 2015
Alere Receives FDA Clearance for Alere™ i Strep A Rapid Molecular Test Apr 02 2015
Current report prepared as per the provisions of art. 225 of Law no. 297/2004 Apr 02 2015
Notification of transactions on the Bank’s shares Apr 01 2015
Alior Bank results for 2014 Apr 01 2015
Alior Bank takes over Meritum Bank Apr 01 2015
Issue of series G bonds Apr 01 2015
Issuue of series G bonds Mar 31 2015
Current report drafted according to the stipulations of the 225 article of the Law no. 297/2004 Mar 31 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK